Slipam30 mg

Slipam is indicated for the short-term treatment (generally 7 to 10 days, up to a maximum of 2-4 weeks) of insomnia characterized by difficulty falling asleep, frequent nighttime awakenings, and/or early morning awakening.

• Established/FDA-approved use: short-term management of insomnia in adults.
• Not indicated for chronic, long-term, nightly use; insomnia that persists beyond 7-10 days may indicate an underlying medical or psychiatric condition that should be evaluated.

Slipam does not treat the underlying cause of insomnia and provides only symptomatic relief.

Each capsule of Flurazepam contains Flurazepam hydrochloride equivalent to Flurazepam 15 mg or 30 mg, along with pharmaceutically approved excipients.

Slipam is a long-acting benzodiazepine derivative used as a hypnotic (sleep-inducing) agent. It belongs to the same pharmacologic class as diazepam and chlordiazepoxide but is used specifically for its sedative-hypnotic properties.

Slipam is rapidly metabolized in the liver to an active metabolite, desalkylSlipam, which has a very long elimination half-life (often 40-100+ hours). This means sedative effects, including next-day drowsiness, can persist and accumulate, particularly with repeated nightly dosing.

Slipam belongs to the benzodiazepine class of medicines, specifically classified as a sedative-hypnotic used for the short-term management of insomnia.

Mechanism of Action

Flurazepam exerts its effects by binding to benzodiazepine receptor sites on the GABA-A receptor complex in the central nervous system. This enhances the inhibitory effect of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain, resulting in increased chloride ion conductance, neuronal hyperpolarization, and generalized central nervous system depression.

Pharmacokinetics

Flurazepam is well absorbed after oral administration and undergoes extensive hepatic metabolism (primarily via CYP3A4) into several metabolites, including the pharmacologically active desalkylflurazepam. Because desalkylflurazepam has a prolonged half-life, the sedative/hypnotic effect of Flurazepam may last well beyond a single night and can accumulate with repeated dosing, especially in elderly or hepatically impaired patients.

Slipam is for oral use only. Swallow the capsule whole with water, immediately before bedtime. Do not take Slipam with or immediately after a meal, as this may delay onset of action. Ensure adequate time (at least 7-8 hours) is available for a full night's sleep before taking a dose.

Clinically Significant Drug Interactions

• Opioids: Concomitant use of Slipam with opioid analgesics or cough suppressants can cause profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with no alternative treatment options, at the lowest effective doses.
• Other CNS depressants (alcohol, other benzodiazepines, sedatives, muscle relaxants, general anesthetics, antihistamines): Additive central nervous system and respiratory depression can occur; avoid concurrent use where possible.
• CYP3A4 inhibitors (e.g., cimetidine, erythromycin, ketoconazole, itraconazole, protease inhibitors): May decrease metabolism of Slipam, increasing plasma levels and prolonging sedative effects.
• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): May increase metabolism of Slipam, reducing its effectiveness.

Common Side Effects

• Daytime drowsiness, dizziness, and lightheadedness
• Ataxia (unsteady gait), staggering, and increased risk of falls (especially in the elderly)
• Headache
• Nausea, vomiting, heartburn, and upset stomach
• Dry mouth, bitter taste

Less Common but Serious Side Effects

• Complex sleep-related behaviors (sleep-walking, sleep-driving, or preparing/eating food while not fully awake, with no memory of the event)
• Respiratory depression, particularly when combined with opioids or other CNS depressants (see Interactions and Precautions)
• Paradoxical reactions such as agitation, aggression, hallucinations, or worsened insomnia (more common in children and the elderly)
• Physical dependence and withdrawal symptoms with prolonged use (see Precautions)
• Allergic reactions including rash or, rarely, angioedema

Pregnancy: Slipam is contraindicated during pregnancy. Benzodiazepine hypnotics used for insomnia, including Slipam, have been associated with an increased risk of congenital malformations and fetal harm when taken during pregnancy, without an established therapeutic benefit that would justify this risk. Use in women who are or may become pregnant is not recommended.

Lactation: Slipam and its active metabolites are excreted in human breast milk and may cause sedation, poor feeding, or respiratory depression in a nursing infant. Breastfeeding is generally not recommended while using Slipam; consult a physician to weigh risks and benefits before use.

Boxed Warning (Benzodiazepine Class)

• Concomitant use with opioids: May result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients with no alternative options and use the lowest effective doses.
• Abuse, misuse, and addiction: Slipam carries a risk of abuse and addiction, which can lead to overdose or death. Assess risk before prescribing and monitor patients during treatment.
• Dependence and withdrawal: Continued use can lead to physical dependence. Abrupt discontinuation or rapid dose reduction after prolonged use may precipitate withdrawal reactions, including seizures, which can be life-threatening. Discontinue by gradual taper under medical supervision.

Other Precautions

• Elderly patients: Increased sensitivity to sedative effects, prolonged clearance due to the long half-life, and higher risk of falls, confusion, and injury. Slipam is generally avoided or used at the lowest effective dose (15 mg) in this population.
• Hepatic or renal impairment: Clearance of Slipam and its active metabolite is prolonged; use with caution and at reduced doses.
• Respiratory disease/untreated sleep apnea: Use with caution in patients with compromised respiratory function or untreated obstructive sleep apnea, as Slipam can further suppress respiratory drive.
• History of substance use disorder: Increased risk of misuse and dependence; use with heightened caution and close monitoring.
• Next-day impairment: Due to its long half-life, Slipam may impair driving, operation of machinery, and cognitive function the day after use, especially at higher doses or in the elderly.
• Not for long-term use: Slipam should be limited to short courses (generally no more than 2-4 weeks) with periodic reassessment; it is not intended for continuous long-term therapy.

Overdose of Slipam, especially in combination with alcohol or other CNS depressants, can cause severe central nervous system depression, including confusion, extreme drowsiness, impaired coordination, diminished reflexes, respiratory depression, coma, and death.

If an overdose of Slipam is suspected, seek immediate emergency medical attention or contact a poison control center right away. Management is supportive and may include airway protection, monitoring of vital signs, and, in a hospital setting, the benzodiazepine antagonist flumazenil (used with caution due to seizure risk). Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. As a controlled substance, keep in a secure location away from unauthorized access.

• Elderly: Increased sensitivity to sedation and fall risk; start at the lowest dose (15 mg) and monitor closely.
• Children/Adolescents: Safety and efficacy of Slipam have not been established in patients under 15 years of age; not recommended in this population.
• Pregnant women: Contraindicated (see Pregnancy and Lactation).
• Breastfeeding women: Not generally recommended; consult a physician (see Pregnancy and Lactation).
• Hepatic/renal impairment: Use with caution and reduced doses due to prolonged clearance.
• Patients with respiratory disease: Use with caution due to risk of worsened respiratory depression.

Slipam is intended for short-term use only, typically 7 to 10 days, and generally not exceeding 2-4 weeks. Treatment duration and the need for continued therapy should be reassessed periodically by a physician. Long-term, continuous nightly use is not recommended due to the risks of tolerance, dependence, and withdrawal. If discontinuing after prolonged use, Slipam should be tapered gradually under medical supervision rather than stopped abruptly.

Flurazepam belongs to the benzodiazepine class of medications and is further categorized as a sedative-hypnotic. It is a federally controlled substance (Schedule IV) due to its potential for abuse and dependence.

Flurazepam binds to benzodiazepine receptor sites on the GABA-A receptor complex, enhancing the inhibitory action of GABA in the central nervous system. This produces sedation, muscle relaxation, anxiolysis, and hypnosis, making Flurazepam effective for inducing and maintaining sleep.

X

The safety and efficacy of Slipam have not been established in pediatric patients, and its use is not recommended in patients under 15 years of age. Insomnia in children and adolescents should be evaluated by a physician for underlying causes, and non-pharmacologic approaches are generally preferred.